---
title: "Obefazimod (ABX464) in Ulcerative colitis: Pharmacodynamics"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Pharmacodynamics. Topics: miR-124 expression in rectal biopsies and blood: phase 2b induction trial, Serum cytokines: phase 2b induction trial, miR-124 expression and serum IL-17A and IL-6: ABTECT induction trials, miR-124 expression through 96 weeks: phase 2b open-label maintenance study, and 5 further topics. 9 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### miR-124 expression in rectal biopsies and blood: phase 2b induction trial

> “The number of miR-124 copies was determined by ddPCR, at baseline and after 8 weeks of treatment, in rectal biopsies and blood samples from patients who received ABX464 (25, 50, or 100 mg) or placebo during a phase 2b trial (10) (Figure 4).”
> “At week 8, the number of miR-124 copies was significantly higher in the treatment groups than in the placebo group (the mean number of copies/cell: placebo, 746; ABX464 [25, 50, and 100 mg], 8,345, 8,347, and 9,171, respectively; Figure 4b).”
> “At week 8, the number of miR-124 copies was significantly higher in each treatment group than in the placebo group (the mean number of copies/cell: placebo, 28.93; ABX464 [25, 50, and 100 mg], 4,598, 8,517, and 13,753, respectively).”
> “A total of 576 rectal biopsies from 139 patients and 1,104 blood samples from 229 patients who received ABX464 (25, 50, or 100 mg) or placebo were analyzed.”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-2"></a>

### Serum cytokines: phase 2b induction trial

> “For the cell and cytokine (IL1b, IL4, IL6, IL10, IL23, IFNγ, CCL2, TNF-α, and IL17a) analysis in serum samples from patients who received either ABX464 during the phase 2b trial (10), significant changes vs placebo were seen only for IL17a, at all doses, with no dose-dependent effect (Figure 5).”
> “Similarly, a reduction in Th17 population and IL17a expression was observed in serum samples, but it was not dose-dependent (see Discussion).”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-3"></a>

### miR-124 expression and serum IL-17A and IL-6: ABTECT induction trials

> “In both Phase 3 ABTECT trials, Obe-25 and 50 mg significantly enhanced expression of miR-124 in blood (p < 0.0001 vs. PBO) and in rectal and sigmoidal tissue at W8 relative to PBO (p < 0.0001 vs. PBO) (Fig. 1).”
> “In both ABTECT trials, Obe-25 and 50 mg significantly reduced IL-17A levels in serum at W8 compared with PBO (p < 0.0001).”
> “IL-6 levels were decreased by Obe-25 (p = 0.0150) and Obe-50 (p = 0.0039) in serum of pts from ABTECT-1 and ABTECT-2 in comparison to PBO, respectively (Fig. 2).”
> “In the ABTECT induction trials conducted in pts with UC, Obe was associated with enhanced expression of miR-124 and nominally statistically significant reductions in the pro-inflammatory cytokines IL-17A and IL-6.”

Source: [Siegmund et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1049/8433989)

> “IL-17A and IL-6 reflect effects on the Th17 and inflammatory macrophage populations, which are all drivers of mucosal inflammation in both UC and CD.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.6.2-4"></a>

### miR-124 expression through 96 weeks: phase 2b open-label maintenance study

> “Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).”
> “Enhanced expression of miR-124 was observed in both rectal tissue and blood of patients receiving obefazimod 50 mg during the OLM study, including those previously receiving placebo during the induction study (Table S2).”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

<a id="topic-2.1.2.6.2-5"></a>

### miR-124 induction and Th17 cells in human immune cells: in vitro studies

> “In this analysis, ABX464 treatment resulted in significant upregulation of miR-124 levels; specifically, the increases in miR-124 levels were 9-fold in PBMCs (Figure 1a), 7-fold in purified CD4+ cells (Figure 1b), and 9-fold in macrophages (Figure 1c).”
> “ABX464 treatment did not change Th1+ cells but significantly decreased Th17 cells (−39.1%, P = 0.0002) or Th17+ like Th1+ (Figure 2b), confirmed by significant decreases (−50.8%, P < 0.0001) in IL17a-secreting cells (Figure 2c).”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

<a id="topic-2.1.2.6.2-6"></a>

### Dextran sodium sulfate colitis in mice

> “Treatment with ABX464 significantly reversed the increases in several proinflammatory cytokines induced by DSS (GM-CSF, IL10, IL34, TPO, LIF, CXCL12, IL6, and CCL2) and maintained their levels close to those of healthy H2O-treated mice (Figure 7a–c).”
> “ABX464 treatment reversed the DSS-induced upregulation of IL17a-secreting cells (−54.2%, P < 0.0001 vs untreated DSS mice) and maintained them at a level equivalent to that in healthy H2O-treated mice (P > 0.9999) (Figure 8a), which further support the effect of ABX464 on adaptive immunity through the reduction of the Th17-positive and CD4-positive subsets.”

Source: [Apolit et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10132720/)

> “ABX464 treatment strongly attenuated DSS-induced colitis in mice and produced a long-term protection against prolonged DSS-exposure after drug cessation.”
> “However, RNA profiling analysis revealed the capacity of ABX464 to induce the expression of IL-22, a cytokine involved in colitis tissue repair, both in DSS-treated mice and in LPS-stimulated bone marrow-derived macrophages.”
> “Importantly, anti-IL-22 antibodies significantly reduced the protective effect of ABX464 on colitis in DSS-treated mice.”

Source: [Chebli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5501810/)

<a id="topic-2.1.2.6.2-7"></a>

### Cytokine and chemokine levels under dysregulated inflammatory conditions: preclinical studies

> “Under dysregulated inflammatory conditions in preclinical studies, enhanced expression of miR-124 resulted in stabilized levels of multiple cytokines and chemokines, bringing them back to homeostatic levels.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

<a id="topic-2.1.2.6.2-8"></a>

### Anti-fibrotic activity in human intestinal fibroblasts and chronic TNBS colitis in mice

> “Our results were as follows: in vitro, obefazimod induced a statistically significant 50% reduction in PRO-C3 at day 12, compared with the IBD-FC condition and upadacitinib (live-cell–adjusted, p<0.0001 vs. IBD-FC).”
> “Additionally, cell-number–adjusted analysis showed significant α-SMA reduction by obefazimod indicating a strong inhibition of fibroblast activation (p< 0.0001 vs. IBD-FC, as shown below).”
> “Moreover, results from this initial experiment showed a reduction in the fibrosis score and collagen deposition was reduced by approximately 52% with day 5 dosing and approximately 42% with day 20 dosing in the Sirius Red assay, whereas thalidomide as a positive control achieved approximately 24%.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.6.2-9"></a>

### Nonclinical toxicology and genotoxicity

> “The toxicity of obefazimod and ABX464-N-Glu was studied in a range of rodent and non-rodent species (rats, rabbits, dogs, cynomolgus and marmoset monkeys, and minipigs) with treatment durations ranging from 2 weeks to 6 or 9 months.”
> “Obefazimod had no significant adverse effects on the nervous and respiratory systems, or on cardiovascular function.”
> “Obefazimod and ABX464-N-Glu were found to be non-genotoxic.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
